The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.

Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...

Gene Therapy: "It is so new ... I wanted to see more success stories before I committed to it," said Davis, who is studying ...

Sonos (SONO – Research Report) received a Hold rating and a $0.00 price target from Craig-Hallum analyst Alex Fuhrman on September 26.

In a report released on September 27, Keith Weiss from Morgan Stanley maintained a Hold rating on Intuit (INTU – Research Report), with a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Real Madrid are second, four points behind leaders Barcelona and two ahead of third-place Atletico Madrid.